Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir in genotype 1b chronic hepatitis C
NCT00621296Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jan 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telaprevir in hepatitis C (HCV), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration. Started Jan 2008; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00621296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621296.